NCT03165396

Brief Summary

According to the inclusion and exclusion criteria, elderly patients undergoing elective orthopedic surgery were randomly divided into four groups. The different combinations of propofol and sevoflurane were used in the four groups: 1 day before surgery, after patients become wide-awake, and 3 days, 7 days, and 3 months after surgery, the patient's cognitive function was evaluated using a professional cognitive scale and other indicators. Finally, statistical analysis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 10, 2016

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

May 17, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 24, 2017

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed
Last Updated

May 25, 2018

Status Verified

May 1, 2017

Enrollment Period

1.7 years

First QC Date

May 17, 2017

Last Update Submit

May 23, 2018

Conditions

Keywords

mild cognitive impairment

Outcome Measures

Primary Outcomes (1)

  • Evidence of clinically cognitive function decline :Apolipoprotein J(ApoJ)

    Measurement by ELISA kit

    Change from Baseline Apolipoprotein J at 7 days

Secondary Outcomes (3)

  • Evidence of clinically cognitive function decline :Soluble CD14(sCD14)

    Change from Baseline Soluble CD14 at 7 days

  • Mini mental Examination(MMSE)

    preoperative 24 hours , 7 days post surgery

  • Montreal Cognitive Assessment(MoCA)

    preoperative 24 hours ,7 days post surgery

Study Arms (4)

Propofol

EXPERIMENTAL

administrated Target Controlled Infusion (TCI)of propofol (Cp 2.0\~2.5μg/ml )for maintaining

Drug: Propofol

1.2 μg/ml Propofol

EXPERIMENTAL

administrated Target Controlled Infusion (TCI)of propofol (Cp 1.2 μg/ml )combined with appropriate sevoflurane for maintaining

Drug: PropofolDrug: Sevoflurane

0.6 μg/ml Propofol

EXPERIMENTAL

administrated Target Controlled Infusion (TCI)of propofol (Cp 0.6 μg/ml )combined with appropriate sevoflurane for maintaining

Drug: PropofolDrug: Sevoflurane

Sevoflurane

EXPERIMENTAL

administrated 1.3 minimum alveolar concentration(MAC ) sevoflurane for maintaining

Drug: Sevoflurane

Interventions

Propofol is the most common clinical anesthetics.

0.6 μg/ml Propofol1.2 μg/ml PropofolPropofol

Sevoflurane is the most common clinical anesthetics.

0.6 μg/ml Propofol1.2 μg/ml PropofolSevoflurane

Eligibility Criteria

Age50 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Elective orthopaedic surgery
  • American Society of Anesthesiologists physical status: II

You may not qualify if:

  • Neurological diseases that may affect cognitive function (e.g., subdural hematoma)
  • Hypothyroidism
  • Alcoholic dementia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Third Central Hospital of Tianjin

Tianjin, Tianjin Municipality, 022, China

RECRUITING

MeSH Terms

Conditions

Cognitive Dysfunction

Interventions

PropofolSevoflurane

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsMethyl EthersEthersHydrocarbons, FluorinatedHydrocarbons, Halogenated

Central Study Contacts

Haiyun Wang

CONTACT

Yimeng Chen

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2017

First Posted

May 24, 2017

Study Start

November 10, 2016

Primary Completion

August 1, 2018

Study Completion

November 1, 2018

Last Updated

May 25, 2018

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will share

Locations